Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Mach7 Technologies ( (AU:M7T) ) is now available.
Mach7 Technologies has announced the appointment of Daniel Lee as their new Chief Financial Officer, effective September 25, 2025. With nearly 20 years of experience in driving growth and profitability in various sectors, including SaaS and healthcare technology, Lee is expected to play a crucial role in supporting Mach7’s strategic transformation and growth ambitions, enhancing shareholder value.
The most recent analyst rating on (AU:M7T) stock is a Buy with a A$0.81 price target. To see the full list of analyst forecasts on Mach7 Technologies stock, see the AU:M7T Stock Forecast page.
More about Mach7 Technologies
Mach7 Technologies (ASX:M7T) is a leading provider of medical imaging software, offering advanced data management and diagnostic viewing solutions to healthcare organizations globally. Their flagship product, the Mach7 Enterprise Imaging Solution (EIS), integrates a Vendor Neutral Archive (VNA), the eUnity Enterprise Diagnostic Viewer, and diagnostic workflow applications, providing flexibility and scalability for diverse healthcare needs.
Average Trading Volume: 296,607
Technical Sentiment Signal: Sell
Current Market Cap: A$74.01M
For detailed information about M7T stock, go to TipRanks’ Stock Analysis page.